Suggested remit: To appraise the clinical and cost effectiveness of olaparib in combination with bevacizumab within its marketing authorisation as maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy.
 
Status In progress
Process STA 2018
ID number 1652

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 11 November 2019 - 09 December 2019

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
29 April 2019 In progress, DHSC Referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance